Treatment of antiphospholipid syndrome beyond anticoagulation

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the present time, treatment is primarily focused on anticoagulation. However, there is increasing awareness of the mechanisms involved in APS pathogenesis, which has led to the trial of novel therapies targeting those mechanisms. Following a brief review of the etiopathogenesis of and current management strategies in APS, this paper focuses on the evidence for these potential, targeted APS treatments, e.g., hydroxychloroquine, statins, rituximab, belimumab, eculizumab, defibrotide, sirolimus, and peptide therapy.

Original languageEnglish (US)
Pages (from-to)53-62
Number of pages10
JournalClinical Immunology
Volume206
DOIs
StatePublished - Sep 2019
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Treatment of antiphospholipid syndrome beyond anticoagulation'. Together they form a unique fingerprint.

Cite this